皮下注射干扰素预防多发性硬化的复发和病残(Pre-vention of Relapses and Disabilityby Interferon-β-1a Subcutane-ously in Multiple Sclerosis,PRISMS)研究曾证实,复发-缓解多发性硬化(Multiple Sclerosis,MS)患者经干扰素-β-1...皮下注射干扰素预防多发性硬化的复发和病残(Pre-vention of Relapses and Disabilityby Interferon-β-1a Subcutane-ously in Multiple Sclerosis,PRISMS)研究曾证实,复发-缓解多发性硬化(Multiple Sclerosis,MS)患者经干扰素-β-1a 22和44mcg每周3次(tiw)为时2年的治疗后,其临床和MRI结果均明显好于对照组。展开更多
文摘皮下注射干扰素预防多发性硬化的复发和病残(Pre-vention of Relapses and Disabilityby Interferon-β-1a Subcutane-ously in Multiple Sclerosis,PRISMS)研究曾证实,复发-缓解多发性硬化(Multiple Sclerosis,MS)患者经干扰素-β-1a 22和44mcg每周3次(tiw)为时2年的治疗后,其临床和MRI结果均明显好于对照组。